* Says drug shows no difference in disease response
* Drug being studied in non-small cell lung cancer
* Shares down 2 pct pre-market
March 17 (Reuters) - Human Genome Sciences Inc HGSI.O said data from a mid-stage trial of its experimental lung cancer drug showed the drug did not improve progression-free survival or disease response, sending its shares down 2 percent before the bell.
The drug, mapatumumab, was studied in combination with chemotherapy drugs paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
The company said the drug was well tolerated in the study, but did not give any other details.
Full details of the trial will be presented at a scientific meeting later in the year, the company said in a statement.
Shares of the company fell 2 percent at $31.21 in premarket trade. They closed at $31.71 Tuesday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Unnikrishnan Nair)